179 related articles for article (PubMed ID: 30051483)
21. A high-density tissue microarray from patients with clinically localized prostate cancer reveals ERG and TATI exclusivity in tumor cells.
Lippolis G; Edsjö A; Stenman UH; Bjartell A
Prostate Cancer Prostatic Dis; 2013 Jun; 16(2):145-50. PubMed ID: 23459095
[TBL] [Abstract][Full Text] [Related]
22. Molecular profiling of ETS and non-ETS aberrations in prostate cancer patients from northern India.
Ateeq B; Kunju LP; Carskadon SL; Pandey SK; Singh G; Pradeep I; Tandon V; Singhai A; Goel A; Amit S; Agarwal A; Dinda AK; Seth A; Tsodikov A; Chinnaiyan AM; Palanisamy N
Prostate; 2015 Jul; 75(10):1051-62. PubMed ID: 25809148
[TBL] [Abstract][Full Text] [Related]
23. Combined analysis of TMPRSS2-ERG and TERT for improved prognosis of biochemical recurrence in prostate cancer.
Sabaliauskaite R; Jarmalaite S; Petroska D; Dasevicius D; Laurinavicius A; Jankevicius F; Lazutka JR
Genes Chromosomes Cancer; 2012 Aug; 51(8):781-91. PubMed ID: 22505341
[TBL] [Abstract][Full Text] [Related]
24. Loss of KLK4::KLKP1 pseudogene expression by RNA chromogenic in-situ hybridization is associated with PTEN loss and increased risk of biochemical recurrence in a cohort of middle eastern men with prostate cancer.
Bakker A; Slack JC; Palanisamy N; Carskadon S; Ghosh S; Khalifeh I; Bismar TA
J Cancer Res Clin Oncol; 2023 Jul; 149(7):3721-3728. PubMed ID: 35982181
[TBL] [Abstract][Full Text] [Related]
25. ERG protein expression and gene rearrangements are present at lower rates in metastatic and locally advanced castration-resistant prostate cancer compared to localized disease.
Teng LH; Wang C; Bégin LR; Dolph M; Yilmaz A; Trpkov K; Donnelly B; Bismar TA
Urology; 2013 Aug; 82(2):394-9. PubMed ID: 23746715
[TBL] [Abstract][Full Text] [Related]
26. High alpha-methylacyl-CoA racemase (AMACR) is associated with ERG expression and with adverse clinical outcome in patients with localized prostate cancer.
Box A; Alshalalfa M; Hegazy SA; Donnelly B; Bismar TA
Tumour Biol; 2016 Sep; 37(9):12287-12299. PubMed ID: 27271990
[TBL] [Abstract][Full Text] [Related]
27. Novel dual-color immunohistochemical methods for detecting ERG-PTEN and ERG-SPINK1 status in prostate carcinoma.
Bhalla R; Kunju LP; Tomlins SA; Christopherson K; Cortez C; Carskadon S; Siddiqui J; Park K; Mosquera JM; Pestano GA; Rubin MA; Chinnaiyan AM; Palanisamy N
Mod Pathol; 2013 Jun; 26(6):835-48. PubMed ID: 23348902
[TBL] [Abstract][Full Text] [Related]
28. Collision tumors revealed by prospectively assessing subtype-defining molecular alterations in 904 individual prostate cancer foci.
Fontugne J; Cai PY; Alnajar H; Bhinder B; Park K; Ye H; Beg S; Sailer V; Siddiqui J; Blattner-Johnson M; Croyle JA; Noorzad Z; Calagua C; MacDonald TY; Axcrona U; Bogaard M; Axcrona K; Scherr DS; Sanda MG; Johannessen B; Chinnaiyan AM; Elemento O; Skotheim RI; Rubin MA; Barbieri CE; Mosquera JM
JCI Insight; 2022 Feb; 7(4):. PubMed ID: 35050902
[TBL] [Abstract][Full Text] [Related]
29. Molecular alterations in prostate cancer and association with MRI features.
Lee D; Fontugne J; Gumpeni N; Park K; MacDonald TY; Robinson BD; Sboner A; Rubin MA; Mosquera JM; Barbieri CE
Prostate Cancer Prostatic Dis; 2017 Dec; 20(4):430-435. PubMed ID: 28762374
[TBL] [Abstract][Full Text] [Related]
30. Urine TMPRSS2:ERG fusion transcript integrated with PCA3 score, genotyping, and biological features are correlated to the results of prostatic biopsies in men at risk of prostate cancer.
Cornu JN; Cancel-Tassin G; Egrot C; Gaffory C; Haab F; Cussenot O
Prostate; 2013 Feb; 73(3):242-9. PubMed ID: 22821767
[TBL] [Abstract][Full Text] [Related]
31. Clonal evaluation of prostate cancer foci in biopsies with discontinuous tumor involvement by dual ERG/SPINK1 immunohistochemistry.
Fontugne J; Davis K; Palanisamy N; Udager A; Mehra R; McDaniel AS; Siddiqui J; Rubin MA; Mosquera JM; Tomlins SA
Mod Pathol; 2016 Feb; 29(2):157-65. PubMed ID: 26743468
[TBL] [Abstract][Full Text] [Related]
32. SPINK1 protein expression and prostate cancer progression.
Flavin R; Pettersson A; Hendrickson WK; Fiorentino M; Finn S; Kunz L; Judson GL; Lis R; Bailey D; Fiore C; Nuttall E; Martin NE; Stack E; Penney KL; Rider JR; Sinnott J; Sweeney C; Sesso HD; Fall K; Giovannucci E; Kantoff P; Stampfer M; Loda M; Mucci LA
Clin Cancer Res; 2014 Sep; 20(18):4904-11. PubMed ID: 24687926
[TBL] [Abstract][Full Text] [Related]
33. Insulin-like growth factor 1 receptor affects the survival of primary prostate cancer patients depending on TMPRSS2-ERG status.
Mancarella C; Casanova-Salas I; Calatrava A; García-Flores M; Garofalo C; Grilli A; Rubio-Briones J; Scotlandi K; López-Guerrero JA
BMC Cancer; 2017 May; 17(1):367. PubMed ID: 28545426
[TBL] [Abstract][Full Text] [Related]
34. Immunohistochemical ETS-related gene detection in a Japanese prostate cancer cohort: diagnostic use in Japanese prostate cancer patients.
Furusato B; van Leenders GJ; Trapman J; Kimura T; Egawa S; Takahashi H; Furusato M; Visakorpi T; Hano H
Pathol Int; 2011 Jul; 61(7):409-14. PubMed ID: 21707844
[TBL] [Abstract][Full Text] [Related]
35. A Prospective Study of the Association between Physical Activity and Risk of Prostate Cancer Defined by Clinical Features and TMPRSS2:ERG.
Pernar CH; Ebot EM; Pettersson A; Graff RE; Giunchi F; Ahearn TU; Gonzalez-Feliciano AG; Markt SC; Wilson KM; Stopsack KH; Gazeeva E; Lis RT; Parmigiani G; Rimm EB; Finn SP; Giovannucci EL; Fiorentino M; Mucci LA
Eur Urol; 2019 Jul; 76(1):33-40. PubMed ID: 30301696
[TBL] [Abstract][Full Text] [Related]
36. Racial Variations in Prostate Cancer Molecular Subtypes and Androgen Receptor Signaling Reflect Anatomic Tumor Location.
Faisal FA; Sundi D; Tosoian JJ; Choeurng V; Alshalalfa M; Ross AE; Klein E; Den R; Dicker A; Erho N; Davicioni E; Lotan TL; Schaeffer EM
Eur Urol; 2016 Jul; 70(1):14-17. PubMed ID: 26443432
[TBL] [Abstract][Full Text] [Related]
37. Association of SPINK1 expression and TMPRSS2:ERG fusion with prognosis in endocrine-treated prostate cancer.
Leinonen KA; Tolonen TT; Bracken H; Stenman UH; Tammela TL; Saramäki OR; Visakorpi T
Clin Cancer Res; 2010 May; 16(10):2845-51. PubMed ID: 20442300
[TBL] [Abstract][Full Text] [Related]
38. ERG expression in prostate cancer: the prognostic paradox.
Taris M; Irani J; Blanchet P; Multigner L; Cathelineau X; Fromont G
Prostate; 2014 Nov; 74(15):1481-7. PubMed ID: 25175352
[TBL] [Abstract][Full Text] [Related]
39. Nuclear C-MYC expression level is associated with disease progression and potentially predictive of two year overall survival in prostate cancer.
Zeng W; Sun H; Meng F; Liu Z; Xiong J; Zhou S; Li F; Hu J; Hu Z; Liu Z
Int J Clin Exp Pathol; 2015; 8(2):1878-88. PubMed ID: 25973080
[TBL] [Abstract][Full Text] [Related]
40. Incidental prostate cancer in Asian men: high prevalence of incidental prostatic adenocarcinoma in Chinese patients undergoing radical cystoprostatectomy for treatment of bladder cancer and selection of candidates for prostate-sparing cystectomy.
Yang X; Monn MF; Liu L; Liu Y; Su J; Lyu T; Gong Y; Wang L; Davidson DD; Cheng L
Prostate; 2015 Jun; 75(8):845-54. PubMed ID: 25704311
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
